Nordic Nanovector - Completion of annual general meeting

The Transaction is expected to be consummated on or around 3 July 2023. The Transaction is expected to be consummated on or around3 July 2023. About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Ludvik Sandnes, Interim CEO & CFO...

The Transaction is expected to be consummated on or around 3 July 2023.

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Ludvik Sandnes, Interim CEO & CFO
Cell: +47 907 43 017
Email: ir@nordicnanovector.com 

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/nordic-nanovector--completion-of-annual-general-meeting-301865940.html